NewsHKSubscribe
RegulatorySRPT

Sarepta Therapeutics names Michael Severino CEO as rare-disease sector tests its next pipeline cycle

The rare-disease genetic medicine sector is pressing into a new commercial and pipeline cycle, with approved gene therapies requiring broader distribution reach and next-generation siRNA programs advancing toward proof-of-concept…

By Harlan Prescott·July 27, 2026·二〇二六年七月二十七日·2 min read

Source · 來源

sec.gov

Share · 分享
Xinfw
← Back to the News DeskFiled · Regulatory

Related Dispatches

相關報導
News Desk →
  1. 01Regulatory

    Anteris Technologies names Brent Moen CFO in cross-border medtech finance shift

    For an emerging growth medical technology company operating out of Australia while listed on a US exchange, the choice of…

    September 8, 2026 · 2 min

  2. 02Regulatory

    Nova Minerals antimony equipment lands at Port MacKenzie, Alaska ahead of 2027 production target

    Against the backdrop of mounting pressure on Western governments to build domestic critical mineral supply chains, Nova…

    September 8, 2026 · 2 min

  3. 03Regulatory

    TuHURA Biosciences draws $1.5 million from Parkview revolving facility for general corporate use

    In the pre-commercial phase of the biotech cycle, how a company bridges its cash requirements between milestones shapes the…

    September 7, 2026 · 2 min

Elsewhere on the Desk

All Dispatches →
Crypto加密

Bitcoin's correlation with US equities hits decade low as rate path debate intensifies

September 8, 2026 · 2 min

Macro

Bitmine's Ethereum stack reaches nearly 6 million as crypto treasury valuation hits $15.7 billion

September 8, 2026 · 2 min

World

Trump targets Bombardier and bets on midterm convention as US debt crosses $40 trillion

September 8, 2026 · 2 min

Macro

Philip Morris International raises full-year 2026 earnings guidance

September 8, 2026 · 2 min